glp 1 shortage ending Drugmakers and pharmacists battle over who gets to make obesity drugs FDA Phasing Out Compounded GLP-1

Indirect evidence supporting a possible benefit of methylation cycle supplements include findings of increased homocysteine in the cerebrospinal fluid of CFS and fibromyalgia patients

The appetite-suppressing effect is stronger

The FDA removed tirzepatide from its drug shortage list in late 2024, which changed the legal landscape for compounding

Most or all of these are common in women who are overweight: Ultra-processed foods Low fiber intake Low protein diets Imbalanced gut flora Lack of short-chain fatty acids Chronic inflammation Poor quality sleep Chronic stress or high cortisol Obesity Insulin resistance/prediabetes Poor vagal nerve function Aging The critical point here is that all but one of those factors are largely or totally within our control

(May check a serum level 2 hours after the load.) This is not often done, but could be considered for patients with unusual pharmacokinetics (e.g., morbid obesity)

Lykkegaard, K